Zobrazeno 1 - 10
of 1 302
pro vyhledávání: '"G. A. Finlay"'
Autor:
Stott, Henry G., Hodgkinson, Francis, Pigott, R. J. S., Thomas, James W., Roberts, Thomas N., Dean, F. W., Foster, E. H., Reinicker, Norman G., Smith, H. L. H.
Publikováno v:
Journal of Fluids Engineering; January 1916, Vol. 38 Issue: 1 p673-686, 14p
Publikováno v:
Journal of Hospital Medicine. 9:116-119
Early detection of an impending cardiac or pulmonary arrest is an important focus for hospitals trying to improve quality of care. Unfortunately, all current early warning systems suffer from high false-alarm rates. Most systems are based on the Modi
Publikováno v:
EFSA Journal. Dec2024, Vol. 22 Issue 12, p1-201. 201p.
Autor:
Chen, Xiuqin1,2 (AUTHOR), Zhu, Yujie1 (AUTHOR), Lin, Caihong1 (AUTHOR), Chen, Xinrui1 (AUTHOR), Xiang, Qishen3 (AUTHOR), Liao, Xinyu1,4 (AUTHOR), Liao, Yanni5 (AUTHOR), Yang, Tian1 (AUTHOR), Ding, Tian1 (AUTHOR), Feng, Jinsong1 (AUTHOR) jinsongf@zju.edu.cn
Publikováno v:
CyTA: Journal of Food. 2024, Vol. 22 Issue 1, p1-7. 7p.
Publikováno v:
BMJ Open
Objectives: This study investigates risk of mortality associated with nurses’ assessments of patients by physiological system. We hypothesise that nursing assessments of in-patients performed at entry correlate with in-hospital mortality, and those
Publikováno v:
Feed Research. 2024, Vol. 47 Issue 20, p165-171. 7p.
Autor:
Lee, Kwan‐Woo1 (AUTHOR), Mun, Su‐Hyun2 (AUTHOR), Kim, Yeon‐A2 (AUTHOR), Kim, Hyo‐Rim2 (AUTHOR), Jin, Qinglong2 (AUTHOR), Lee, Min‐Ki2 (AUTHOR), Park, Soo Nam3 (AUTHOR) snpark@swu.ac.kr
Publikováno v:
Skin Research & Technology. Oct2024, Vol. 30 Issue 10, p1-14. 14p.
Publikováno v:
Infectious Diseases in Clinical Practice. 8:218-220
Publikováno v:
Anti-cancer drug design. 16(6)
DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide dihydrochloride) has high experimental antitumor activity and has completed phase I/II clinical trials. It targets both topoisomerase (topo) I and II, but the roles of each of these enzymes in th
Publikováno v:
Oncology research. 11(6)
The action of the anticancer drug amsacrine appears to involve molecular interactions with both DNA and topoisomerase II. It has been shown previously that DNA intercalators can inhibit the action of amsacrine and several other topoisomerase II poiso